A sweeping office development on 28.5 acres comprising 2.8 million square feet over six buildings is poised to be constructed in South San Francisco.

The development, slated for a site bordering San Bruno adjacent to The Shops at Tanforan, is the latest in an intensifying life-science boom on the Peninsula, of which South San Francisco is at the epicenter.

The proposal gained Planning Commission approval last week and will go next before the city councils in South San Francisco and San Bruno for a final signoff. If all goes according to plan, construction will begin this year, with the final phase wrapping up in 2030.

Between 5,000 and 11,000 people would be employed at the campus, depending on tenants, according to a city report, and buildings would range from three to seven stories, with a maximum height of 120 feet dictated by the nearby airport. A new public road running east-west through the site would also be built, as would two parking structures comprising 1,095 spaces.

Plans further indicate a restaurant, bar and park on-site, in addition to infrastructure upgrades including bike lanes, pedestrian space improvements and nearby intersection redesigns to handle increased traffic. City planners hope employees will use car alternatives like public transit to commute to work, given the site’s proximity to the San Bruno BART station adjacent to the Tanforan mall.

The developer, Menlo Park-based Lane Partners, is proposing a community center to also be included, which could be run in conjunction with the city to offer space for nonprofits and community programming. A payment of $25 million to the city would be part of the agreement, to be spent at the city’s discretion, on top of another $50 million in impact fees that would go to affordable housing and infrastructure upgrades.

City planners expressed hope the developments could revitalize the area, which is currently occupied by several industrial warehouses and distribution buildings and large surface level parking lots.

A residential neighborhood directly to the south of the site in San Bruno could also stand to benefit, as the project would include a park space with a walkway, community garden and children’s play area along Tanforan Avenue adjacent to the homes where there are currently truck loading areas.

“The community benefits are great, the design is amazing, it’s going to transform that whole area … I’m fully in support of the project,” Planning Commission Chair Sam Shihadeh said.

The project has been in the works for at least five years as the developer has worked to acquire the parcels that make up the project site. The Planning Commission last year reviewed a proposal that did not include a corner lot at 80 Tanforan Ave., which was added in the most recent plans to include a parking garage.

The first phase of construction is planned to last about two years, and would include the southern buildings, including the restaurant space and community center, which account for 680,000 square feet.

“I think overall we’ll see a net positive from the construction of this project and development of this site,” Planning Commissioner JulieAnn Murphy said, who noted the new road and surrounding street improvements as a particular benefit.

The Tanforan mall is set to undergo a similar transformation into a biotech campus, potentially also with 1,000 units of housing. That project is envisioned as having 2 million or more square feet, although formal plans have yet to be submitted.

The San Bruno City Council plans to meet next week to discuss the Southline project, and the South San Francisco City Council will likely deliberate on the plans mid-July.

The post Large Workplace campus OK’d in South San Francisco | Native Information appeared first on Los Gatos News And Events.

BATON ROUGE – A problem with Scotlandville High’s plumbing flooded a building on campus over the weekend, forcing administrators to cancel in-person classes for most of the week.

The East Baton Rouge Parish School System announced the last-minute closure around 7 pm Sunday night. After three days of virtual learning, all students will be on campus Thursday.

A spokesperson for the school system said a toilet malfunctioned and was stuck continually flushing, causing the water to overflow.

Although students are back on campus, the school’s E Building is still closed for air quality and mold testing.

The post College students returning to Scotlandville Excessive on Thursday, plumbing mishap flooded campus over the weekend appeared first on Los Gatos News And Events.

BATON ROUGE – A problem with Scotlandville High’s plumbing flooded a building on campus over the weekend, forcing administrators to cancel in-person classes for most of the week.

The East Baton Rouge Parish School System announced the last-minute closure around 7 pm Sunday night. After three days of virtual learning, all students will be on campus Thursday.

A spokesperson for the school system said a toilet malfunctioned and was stuck continually flushing, causing the water to overflow.

Although students are back on campus, the school’s E Building is still closed for air quality and mold testing.

The post College students returning to Scotlandville Excessive on Thursday, plumbing mishap flooded campus over the weekend appeared first on Los Gatos News And Events.

Significant investment will enable world-class discovery research, innovation in data science and digital health and collaborations in the Bay Area

BRISBANE, Calif., September 20, 2022–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a state-of-the-art Research & Development (R&D ) facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth.

“Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions,” said Joaquin Duato, Chief Executive Officer, Johnson & Johnson. “On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.”

The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline.

“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC.

Story continues

The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health.

Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy , more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; neuroscience; oncology; and pulmonary hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About Johnson & Johnson Technology
Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease. Guided by Our Credo, we unleash the power of technology for good to drive greater access, equity, and sustainability, and to shape the future of healthcare in the way that only we can.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies; the Company’s ability to satisfy the necessary conditions to consume the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts on the business , or on the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements ” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005339/en/

Contacts

Media:
Jake Sargent
+1 732-524-1090
JSargen3@its.jnj.com

Rachael Jarnagin
+1 415-705-9023
RJarnagi@its.jnj.com

Investor Relations:
Raychel Kruper
+1 732-524-6164
RKruper@its.jnj.com

The post Johnson & Johnson Opens State-of-the-Artwork Science and Know-how Campus in San Francisco Bay Space appeared first on Los Gatos News And Events.

BRISBANE, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the Company) today opened its San Francisco Bay Campus, a state-of-the-art Research & Development (R&D) facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth.

“Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions,” said Joaquin Duato, Chief Executive Officer, Johnson & Johnson. “On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.”

The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline.

“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC.

The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health.

Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy , more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; neuroscience; oncology; and pulmonary hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About Johnson & Johnson Technology

Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease. Guided by Our Credo, we unleash the power of technology for good to drive greater access, equity, and sustainability, and to shape the future of healthcare in the way that only we can.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies; the Company’s ability to satisfy the necessary conditions to consume the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts on the business , or on the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements ” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

The post Johnson & Johnson Opens State-of-the-Artwork Science and Know-how Campus in San Francisco Bay Space appeared first on Los Gatos News And Events.

New 154,000-square-foot facility will provide a West Coast center with a focus on research, innovation, and commercial collaboration across corporate and program areas

TOKYO other SAN FRANCISCO, July 21, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji YasukawaPh.D., “Astellas”) today announced plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-square-foot building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the san francisco area.

Astellas plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center.

The new innovation and research center will include employees across research, technical operations, medical and development, commercial, and relevant administrative support functions. Astellas will invest approximately $70 million to create the new state-of-the-art facility, which will provide lab and co-working spaces to accommodate future growth as it advances a range of innovative cell and gene therapies for patients with limited or no treatment options, including rare diseases and cancer.

“By uniting our business units in the Bay Area, we are creating a dedicated West Coast center in the vibrant South San Francisco corridor alongside other leaders in the biotechnology and pharmaceutical industry,” said Yoshitsugu Shitaka, Ph.D., Chief Scientific Officer at Astellas. “Similar to the Astellas Biomedical Innovation Hub located in the greater Boston area, this new facility will foster even greater levels of collaboration amongst our world-class, multi-disciplinary teams working in cell and gene therapies, development of business opportunities and all those who support our endeavors to create value for patients.”

Astellas expects to complete the building and be operational in summer 2023. Astellas will be the sole occupant of the new building and will spend the next year equipping the interior with state-of-the-art research labs, office spaces, and other amenities specifically designed to accommodate the West Coast employees of Astellas Gene Therapies, Xyphos Biosciences, business development, Rx+® Business Accelerator, and the planned future growth within those units. In addition, the co-location of these businesses allows for more efficient use of space by combining the lab and office facilities into one new building, compared to current independent locations.

Astellas’ VISION is to be at the forefront of healthcare change and to turn innovative science into VALUE for patients. Under this vision, Astellas is focused on bringing life-changing cell and gene therapy treatments to patients suffering from diseases that lack treatment options.

Astellas has already reflected the impact from this matter in its financial forecast of the current fiscal year ending March 31, 2023.

About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

About Astellas Gene Therapies
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Our gene therapy drug discovery engine is built around innovative science, a validated AAV platform, and industry leading internal manufacturing capability with a particular focus on rare diseases of the eye, CNS and neuromuscular system. We will also be advancing additional Astellas gene therapy programs toward clinical investigation. We are based in san franciscowith manufacturing and laboratory facilities in South San Francisco, Calif.and Sanford, NC

About Xyphos Biosciences, Inc., to Astellas Company
Xyphos Biosciences Inc., located in South San Francisco, Calif., is at Astellas Center of Excellence for Cancer Cell Therapy developing medicines to cure solid tumors with a precision, off-the-shelf “Standard Pharmaceutical like Cell Therapy” platform, which can be easily tailored to the needs of individual patients and adapted to multiple disease targets. Utilizing a deep understanding of cancer biology and the tumor microenvironment, we are developing a flexible and versatile platform to direct the body’s immune cells to target single or multiple tumor antigens to fuel a stronger immune response, while avoiding immune rejection. By combining our ACCEL technology, a universal CAR (chimeric antigen receptor), and Universal Cells’ Universal Donor Cells (UDC) technology, we aim to create a unique platform that offers greater speed and flexibility compared to currently approved chimeric antigen receptor cell therapies and expands potential value for as many cancer patients as possible.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in the light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

SOURCE Astellas Pharma Inc.

The post Astellas Unveils Plans to Open New Biotech Campus in South San Francisco appeared first on Los Gatos News And Events.

Use this information to navigate the facility or locate your care provider’s office. To print the map, download the file and print. This will provide the highest quality image.

directions

From the north

Cross the Golden Gate Bridge. Take the Highway 1/19th Avenue exit and go south through the General MacArthur Tunnel which puts you on Park Presidio. At the third traffic light, turn right on Clement Street. Go about two miles and turn right at 42nd Avenue onto the medical center grounds. Patient and visitor parking is located in front of Building 1 and in the free valet parking garage.

From the east

Cross the Bay Bridge and exit at Ninth Street/Civic Center. At the end of the ramp, bear left onto Harrison for one block and then turn right onto Ninth Street and stay to the left. After crossing Market, stay to the left onto Hayes. Turn right on Van Ness. Continue on Van Ness approximately ½ mile and turn left on Geary. Continue on Geary for about four miles and turn right on 42nd Avenue, onto Medical Center grounds. Patient and visitor parking is located in front of Building 1 and in the free valet parking garage.

From the south

Take interstate 280 north. Near San Francisco stay to the left and follow signs to 19th Avenue/Golden Gate Bridge. Stay in the left lanes and at the first traffic light, bear left onto 19th Avenue. Continue on 19th Avenue 3 miles and stay in the left lane as you enter Golden Gate Park. Turn left at the traffic light onto 25th Avenue. Continue on 25th Avenue for about one mile and turn left on Clement. Go one mile and turn right at 42nd Avenue onto the medical center grounds. Patient and visitor parking is located in front of Building 1.

Get custom directions from Google Maps

Additional GPS information

When programming your GPS for directions, use one of the following:

Address:
San Francisco VA Medical Center, 4150 Clement Street
San Francisco, CA 94121
intersection:
Coming soon!
Coordinates: 37°46’54.36″N 122°30’18.43″W

The post Campus Map | VA San Francisco Well being Care appeared first on Los Gatos News And Events.

New research and development campus geared toward a biotech tenant could be headed for South San Francisco, with a seven-story, 166,000-square-foot building proposed for 101 Gull Drive in the city’s East Side neighborhood.

The proposal would develop what is now a vacant 3.7-acre lot surrounded by industrial uses. A 419 parking space 4.5-story parking garage would be attached to the building. Plans also indicate landscaping and outdoor seating areas.

Environmental impact studies are still being conducted, and the proposal will go before the Planning Commission for approvals during a future meeting. Construction is targeted to begin in late summer 2022, with completion in summer of 2024. The lot was sold in 2020 for $14.9 million.

Based on the city’s commercial linkage fees, the developer will be required to pay more than $2.7 million, funds which will be added to the city’s affordable housing fund.

The post Biotech campus proposed in South San Francisco | Native Information appeared first on Los Gatos News And Events.

HAYWARD (CBS SF) – California State University officials announced Wednesday that they will require faculty, staff and students who have access to on-campus facilities to provide proof of a COVID vaccine booster vaccinated by February 2022.

The new requirement stipulates that the booster vaccination must be given by February 28th or six months after receiving the last dose of the original vaccination.

CONTINUE READING: 2 Suspects Arrested for Murdering TV News Crew Security Guard Kevin Nishita; 3. Suspect wanted

Officials said, however, that local circumstances may allow individual campuses to schedule an earlier compliance date for students and unrepresented staff.

“The vaccination, if necessary also a booster vaccination, remains our most effective strategy against infections and serious illnesses,” said CSU Chancellor Joseph I. Castro. “This is especially important given the rapid rise in COVID-19 cases across the state and nation as the Omicron variant spreads. The immediate implementation of the booster requirement will help to reduce the potential spread of the variant on the campuses that will be repopulated in January after the winter break. “

CONTINUE READING: FDA approves first antiviral pill to treat COVID-19

As already announced, the COVID-19 vaccination guideline of the CSU enables students and employees to apply for exceptions for medical and religious reasons.

The announcement came less than 24 hours after Governor Gavin Newsom issued a similar order for the state’s health workers.

In a Twitter video post, Newsom said it was taking steps to ensure there were enough healthy medical staff to handle a possible post-holiday surge in new cases.

MORE NEWS: UPDATE: California Calls for COVID Booster Vaccinations for All Healthcare Workers; Extend testing

“We all watch the news and have heard what President Biden said today about what was happening across the country and the rest of the world with the Omicron variant,” said the governor. “It’s not dissimilar to what’s happening here in the state of California. As a result, we are stepping up our efforts to get people vaccinated, but also to empower people. That’s why we’re going further today and calling for all healthcare workers to be reinforced – get the third admission, or at least the second admission when you get the J&J. “

The post Cal State Universities To Require Booster Photographs For On Campus College students And College – CBS San Francisco appeared first on Los Gatos News And Events.

SAN FRANCISCO (CBS SF) – A suspect was arrested Tuesday after a “non-specific” online threat forced San Francisco State University officials to cancel face-to-face classes.

Campus police, who work with other law enforcement agencies, arrested a person of interest on Tuesday morning over the threat to the SF State campus, the university said. Early Tuesday at 3:11 a.m., the university issued a warning to students, faculty, and staff, instructing students to stay in their dormitories until security officers give the all-clear.

CONTINUE READING: State Sen. Wiener’s Recovery Incentives Act would pay meth addicts to stay sober

The university said it now anticipates that there are no ongoing threats to the campus or community, and students have been given permission to exit the dormitories. Classes were to continue remotely for the rest of the day, and university buildings, including the library, remained closed on Tuesday.

The SFSU communications director told KPIX that a threat of armed violence on campus was posted on social media overnight. The post has since been deleted.

SF State Junior Ruqaiyah Angeles told KPIX it received the alert very early Tuesday morning and later learned of the possible threat of violence

CONTINUE READING: Notorious Norteño gang member “Lil Rhino” has been convicted of attacking prisons

“Scary! You never know what’s going to happen,” said Angeles. “They’re just trying to protect us all and cordoned off the whole school. I don’t know if you were on campus, but all the doors are locked ..”

After initially saying the campus would be closed until 10 a.m., school officials extended the closure to the whole day while detectives examined the threat’s credibility. There was a large police presence on campus.

“All personal training and services for Tuesday, September 28th, should be switched to remote modalities if possible,” the school wrote on Facebook. “The university buildings, including the library, will remain closed. Dormitory students are asked to stay in the campus dormitories until nothing else is communicated. “

NEW: San Francisco State University switched to all remote teaching today. The police are investigating a so-called “anonymous, unspecific threat”.

University buildings are being closed and students should stay in the dormitories until told otherwise. @KPIXtv pic.twitter.com/AWnOohvrXh

– Justin Andrews (@Justin_EAndrews) September 28, 2021

There was no word from campus officials about who had made the threat.

MORE NEWS: Santa Rosa legislature proposes a plan for city-sanctioned sideshow

“Ultimately, I appreciate my school for taking the necessary precautions to protect not only its students, but its staff and the community,” said Angeles

The post Suspect Arrested After On-line Risk Shuts Down San Francisco State Campus – CBS San Francisco appeared first on Los Gatos News And Events.